



3rd Quarter Summary of Activities for WV BMS' RetroDUR Committee by the Marshall Coalition November 2022



## Lock-In Warning Letters sent to Patients and Providers

**July** 

Patients - 3

Providers – 4

Total Letters –7

<u>August</u>

Patients – 2

Providers – 3

Total Letters - 5

<u>September</u>

Patients – 0

Providers – 0

Total Letters - 0

# LOCK-IN LETTERS MAILED

July

0

August

C

September

3





CLINICAL INTERVENTION LETTERS MAILED	JUL	AUG	SEP
Rx of opioid and Benzodiazepine	86	84	22
Dx of GERD w/PPI Therapy >90 days	59	33	9
Dx of DM w/o ACE or ARB	4	7	2
Dx of ASCVD w/o Statin	20	4	2
Rx of GLP-1 Agonist and DPP-4 inhibitor	0	0	0
Dx of CHF w/NSAIDS	12	14	1
Dx of CHF w/Select Drugs	0	0	0
Dx of H. Pylori w/PPI Therapy >14 days	1	0	0
Dx of HFrEF w/Diltiazem or Verapamil	0	3	2
Dx of CHF w/TZDs	0	1	0
Dx of Diabetes and HFrEF w/o SGLT2 Inhibitor	0	4	2
Dx of CHF w/ Dronedarone	0	4	2
MME >=50 w/o Naloxone	79	40	14
Diabetes and Heart Failure w/o Statin	3	17	6
Hepatitis C Dx w/o Treatment	36	16	12
TOTALS	300	224	72

### July Clinical Intervention Feedback

CLINICAL INTERVENTION	USEFUL	MADE CHANGES	NO CHANGES	NO LONGER A PATIENT	NEVER WAS A PATIENT	NOTICE NOT USEFUL	TOTAL FAXES RECEIVED
Rx of Opioid and Benzodiazepine	2	3	4	1		2	9
	_					_	
Dx of GERD w/PPI Therapy >90 days							
Dx of DM w/o ACE or ARB							
Dx of ASCVD w/o Statin	1	1					1
Rx of GLP-1 Agonist and DPP-4 Inhibitor							
Dx of CHF w/NSAIDS							
Dx of CHF w/Select Drugs							
Dx of H. Pylori w/PPI Therapy>14 days							
Dx of HFrEF w/Diltiazem or Verapamil							
Dx of CHF w/TZDs							
Dx of Diabetes and HFrEF w/o SGLT2 Inhibitor	3	3	1				3
Dx of CHF w/ Dronedarone							1
MME >=50 w/o Naloxone			1				1
Diabetes w/o Statin	2	2		1			3
Warning							
Totals	8	9	6	2		2	17

## August Clinical Intervention Feedback

· ·							
					NEVER		
		MADE	NO	NO LONGER	WAS A		TOTAL FAXES
CLINICAL INTERVENTION	USEFUL	CHANGES	CHANGES	A PATIENT	PATIENT	USEFUL	RECEIVED
Rx of Opioid and Benzodiazepine	6	2	1				7
Dx of GERD w/PPI Therapy >90 days	2		2				3
Dx of DM w/o ACE or ARB							
Dx of ASCVD w/o Statin							
Rx of GLP-1 Agonist and DPP-4 Inhibitor							
Dx of CHF w/NSAIDS	1						1
Dx of CHF w/Select Drugs							
Dx of H. Pylori w/PPI Therapy>14 days							
Dx of HFrEF w/Diltiazem or Verapamil							
Dx of CHF w/TZDs							
Dx of Diabetes and HFrEF w/o SGLT2							
Inhibitor							
Dx of CHF w/ Dronedarone							
MME >=50 w/o Naloxone	1	1				1	3
Diabetes w/o Statin							
Warning							
HEP C Fax received	1			1	1		3
TOTALS	10	3	3	1	1	1	17

## September Clinical Intervention Feedback

		MADE	NO	NO LONGER	NEVER WAS A	NOTICE NOT	TOTAL FAXES
CLINICAL INTERVENTION	USEFUL	CHANGES		A PATIENT	PATIENT	USEFUL	RECEIVED
Rx of Opioid and Benzodiazepine			1				1
Dx of GERD w/PPI Therapy >90 days							
Dx of DM w/o ACE or ARB							
Dx of ASCVD w/o Statin							
Rx of GLP-1 Agonist and DPP-4 Inhibitor							
Dx of CHF w/NSAIDS			1				1
Dx of CHF w/Select Drugs							
Dx of H. Pylori w/PPI Therapy>14 days							
Dx of HFrEF w/Diltiazem or Verapamil							
Dx of CHF w/TZDs							
Dx of Diabetes and HFrEF w/o SGLT2 Inhibitor							
Dx of CHF w/ Dronedarone							
MME >=50 w/o Naloxone	2		1				3
Diabetes w/o Statin							
Warning							
HEP C Fax received							
TOTALS	2		3				5

### October Clinical Intervention Feedback thus far

October, 2022	CLINICAL INTERVENTION	USEFUL	MADE CHANGES	NO CHANGES	NO LONGER A PATIENT	NEVER WAS A PATIENT	NOTICE NOT USEFUL	TOTAL FAXES RECEIVED
	Rx of Opioid and Benzodiazepine	1		1	1			3
	Dx of GERD w/PPI Therapy >90 days							
	Dx of DM w/o ACE or ARB							
	Dx of ASCVD w/o Statin							
	Rx of GLP-1 Agonist and DPP-4 Inhibitor							
	Dx of CHF w/NSAIDS							
	Dx of CHF w/Select Drugs							
	Dx of H. Pylori w/PPI Therapy>14 days							
	Dx of HFrEF w/Diltiazem or Verapamil							
	Dx of CHF w/TZDs							
	Dx of Diabetes and HFrEF w/o SGLT2 Inhibitor							
	Dx of CHF w/ Dronedarone							
	MME >=50 w/o Naloxone	1	2		1			3
	Diabetes w/o Statin							
	Warning							
	HEP C Fax received				1			1
	TOTALS	2	2	1	3			7

MME>=Comments: Will discuss at next visit				
Reviewed and made changes				
No longer a patient				
Opioid and Benzo Comments: Patient was rue	de, non c	ompliant, a	nd	
discharged from our practice.				
Patient recently established with me and I am	working	to reduce.		
HEP C Comments: Patient moved to				
Morgantown				
This patient is no longer under my care				

## **Provider Comments**

#### Opioid and Benzo

- Thank you for this! Although I didn't make any changes today, I made a note to discuss with her at next visit.
- He got 10 oxy in May x 1. Are we no longer allowed to treat panic and acute pain?
- Thank you!
- Patient is stable on current regimen
- Patient has terminal cancer
- As always, I evaluate and treat patients with their best interest in mind. I am aware of all the meds and issues the patient has. This is time consuming and has little value, but I understand the issue.

#### ASCVD w/o Statin

• Patient is on Atorvastatin 20 mg daily

#### HEP C

- Patient showed self resolution from lab work collected 3-22-22
- Although HCV antibody was positive, his viral load was not detected meaning he has cleared the virus.





## **Provider Comments**

#### OPIOID AND BENZO

- Medication was prescribed short term for post operative pain. Pt has already discontinued.
- I have inherited this patient who is on multiple controlled substances.

  Lorazepam is rx by his neurologist and is in the process of being weaned.
- Patient recently established with me and am working to decrease.

#### **NALOXONE**

- Patient follows with another physician for routine care and pain meds.
- Naloxone has been prescribed.

#### HEP C

- Patient did not show up as scheduled.
- Patient was approved for the treatment but has been in jail the last few months. After his release he needed further lab work and would not answer or show up. I am always looking for patients who need treated.

#### **GERD**

• Controlled and Tagamet bid and PPI







## RETURNED LETTER COUNT

JULY	25	8.3%
AUG	45	20.08%
SEPT	18	25%
TOTAL	88	14%



# DUR HOTLINE CALLS RECEIVED

## JULY - SEPTEMBER CALLS 12 **PHARMACISTS PRESCRIBERS** PATIENT CALLS **TOTAL CALLS** 32





## REVIEW COUNTS TOTAL PATIENTS

, , , , , , , , ,	Jul			Aug			Sep			
	Reviews	Letters	Lockins	Reviews	Letters	Lockins	Reviews	Letters	Lockins	TOTAL
Dx of AFib & Stage 4+ CKD w/Sotalol	1	. 0								1
Dx of ASCVD w/o Statin	25	18		23	15		3	3 1		85
Dx of CHF w/Dronedarone										0
Dx of CHF w/NSAIDS	15	12		14	14		2	! 1		58
Dx of CHF w/TZDs				1	1					2
DX of Diabetes w/o Statin	34	. 33		19	17		13	3 13		129
Dx of DM w/o ACE or ARB	10	6		12	7		4	4		43
Dx of GERD w/PPI Therapy >90 Days	57	50		32	28		10	10		187
Dx of H.Pylori w/PPI Therapy >14 Days	1	. 1								2
Dx of HEPC w/o Treatment	129	126		69	63		42	2 38		467
Dx of HFrEF w/Diltiazem or Verapamil	1	. 0		2	2		2	. 2		9
Dx of HFrEF w/o SGLT2 Inhibitor	19	14		15	10		3	3		64
MME >=50 w/o Naloxone RX	101	. 96		51	45		23	3 18		334
Rx of Opioid & Benzodiazepine	97	62		64	51		22	2 14		310
Lockin	6	3	C	3	2	. (	) 2	2 0	1	. 17
Grand Total	496	421	C	305	255		126	5 104	. 1	1708

## 2022 3RD QUARTER Newsletter

Posted on BMS Website





